

Chordate will be granted a fourth patent in the USA

Chordate Medical Holding AB (Publ.) announces that the United States Patent and Trademark Office has issued a decision to grant Chordate's patent application US 17/942,912 from 2022.

The patent application relates to the treatment of headaches, focusing on protecting the company's product Ozilia Migraine. The granting of the application means that a fourth U.S. patent is added to a growing patent family focused on headache treatment, which the company has been building since 2011.

"One of the three cornerstones of our strategic efforts to build shareholder value is to fulfill our patent strategy. The intellectual property defense of our technology to support our ongoing business development is an essential part of what we consider core values in the company," says Anders Weilandt, CEO of Chordate Medical.

Chordate Medical today holds 79 patents across 32 countries and 9 patent families, covering various aspects of the company's treatment technologies. The patent families deal with various aspects of Chordate's technology and are designed to provide the best possible protection for the inventions that is the basis for the company's products.

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).

Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Press Release
03 May 2024 13:45:00 CEST

CHORDATE
M E D I C A L

Attachments

[Chordate will be granted a fourth patent in the USA](#)